Pivikto 150 mg Tablet

Product Description

Pivikto 150 mg Tablet serves as an innovative treatment option for individuals battling advanced hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer, specifically in postmenopausal women and men. As a phosphatidylinositol 3-kinase (PI3K) inhibitor, Pivikto works by targeting specific pathways involved in cancer cell growth, providing a mechanism for combating tumors that are resistant to traditional hormonal therapies. This medication is particularly beneficial for patients who possess mutations in the PIK3CA gene and have not responded to other hormonal treatments, as it can be effectively combined with fulvestrant to enhance therapeutic outcomes. Its crucial for patients to consult their healthcare provider regarding potential side effects and interactions, as Pivikto may not be suitable for everyone. Regular monitoring is recommended to ensure safety and efficacy during treatment. By understanding how Pivikto functions and its role in advanced breast cancer management, patients can make informed decisions about their treatment options. Always discuss your medical history and current medications with your healthcare professional before starting this therapy.